Stock-Based Compensation (Tables)

9 Months Ended

Sep. 28, 2019

Stockholders Equity Note [Abstract]

Schedule of stock-based compensation expense

The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations and comprehensive loss (in thousands):

	Fiscal Three Months Ended				Fiscal Nine Months Ended
	September 28, 2019		September 29, 2018		September 28, 2019		September 29, 2018
Cost of revenue	$	6	$	1	$	14	$	4
Research, development and clinical trials expenses		35		9		67		28
Selling, general and administrative expenses		254		21		491		60
	$	295	$	31	$	572	$	92